Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer

被引:0
作者
A Wu
Q Zeng
T H Kang
S Peng
E Roosinovich
S I Pai
C-F Hung
机构
[1] Johns Hopkins Medical Institutions,Department of Pathology
[2] Head and Neck Cancer,Department of Otolaryngology
[3] Johns Hopkins Medical Institutions,Department of Oncology
[4] Johns Hopkins Medical Institutions,undefined
[5] Imperial College School of Medicine,undefined
来源
Gene Therapy | 2011年 / 18卷
关键词
DNA vaccine; E6; head and neck cancer; HPV; invariant chain; PADRE;
D O I
暂无
中图分类号
学科分类号
摘要
Human papillomavirus (HPV), particularly type 16, has been associated with a subset of head and neck cancers. The viral-encoded oncogenic proteins E6 and E7 represent ideal targets for immunotherapy against HPV-associated head and neck cancers. DNA vaccines have emerged as attractive approaches for immunotherapy due to its simplicity, safety and ease of preparation. Intradermal administration of DNA vaccine by means of gene gun represents an efficient method to deliver DNA directly into dendritic cells for priming antigen-specific T cells. We have previously shown that a DNA vaccine encoding an invariant chain (Ii), in which the class II-associated Ii peptide (CLIP) region has been replaced by a Pan-DR-epitope (PADRE) sequence to form Ii-PADRE, is capable of generating PADRE-specific CD4+ T cells in vaccinated mice. In the current study, we hypothesize that a DNA vaccine encoding Ii-PADRE linked to E6 (Ii-PADRE-E6) will further enhance E6-specific CD8+ T cell immune responses through PADRE-specific CD4+ T-helper cells. We found that mice vaccinated with Ii-PADRE-E6 DNA generated comparable levels of PADRE-specific CD4+ T-cell immune responses, as well as significantly stronger E6-specific CD8+ T-cell immune responses and antitumor effects against the lethal challenge of E6-expressing tumor compared with mice vaccinated with Ii-E6 DNA. Taken together, our data indicate that vaccination with Ii-E6 DNA with PADRE replacing the CLIP region is capable of enhancing the E6-specific CD8+ T-cell immune response generated by the Ii-E6 DNA. Thus, Ii-PADRE-E6 represents a novel DNA vaccine for the treatment of HPV-associated head and neck cancer and other HPV-associated malignancies.
引用
收藏
页码:304 / 312
页数:8
相关论文
共 148 条
[1]  
Murdoch D(2007)Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based review Curr Opin Oncol 19 216-221
[2]  
Chung CH(2009)Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications Clin Cancer Res 15 6758-6762
[3]  
Gillison ML(2008)Immunotherapy for head and neck cancer J Biomed Sci 15 275-289
[4]  
Wu AA(2000)Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma Clin Cancer Res 6 4171-4175
[5]  
Niparko KJ(2002)Papillomaviruses and cancer: from basic studies to clinical application Nat Rev Cancer 2 342-350
[6]  
Pai SI(1997)DNA vaccines Annu Rev Immunol 15 617-648
[7]  
Capone RB(2000)DNA vaccines: immunology, application, and optimization Annu Rev Immunol 18 927-974
[8]  
Pai SI(1996)DNA-based immunization by Nat Med 2 1122-1128
[9]  
Koch WM(1998) transfection of dendritic cells J Exp Med 188 1075-1082
[10]  
Gillison ML(2008)Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization Expert Opin Biol Ther 8 421-439